<![CDATA[지엔티파마 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=17153>Mon, 06 Apr 2026 05:37:07 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[GNT Pharma's Ropesalazine Effective in Treating Dog Dementia]]>https://www.newswire.co.kr/newsRead.php?no=874876Mon, 03 Sep 2018 13:45:00 +0900<![CDATA[GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000]]>https://www.newswire.co.kr/newsRead.php?no=826291Tue, 17 May 2016 11:00:00 +0900<![CDATA[GNTファーマ、血管内治療を受けている脳卒中患者を画期的新薬のマルチターゲット神経保護剤Neu2000で治療する第2相臨床試験のIND承認を取得]]>https://www.newswire.co.kr/newsRead.php?no=826293Tue, 17 May 2016 11:00:00 +0900<![CDATA[GNT Pharma Co., Ltd.和丰田通商株式会社宣布建立战略合作伙伴关系，进一步开发治疗中枢神经系统（CNS）疾病和炎症性疾病的Neu2000和AAD-2004]]>https://www.newswire.co.kr/newsRead.php?no=616515Fri, 13 Apr 2012 11:13:32 +0900<![CDATA[GNT Pharma Co., Ltd. and Toyota Tsusho Corporation Announce Strategic Partnership for Further Development of Neu2000 and AAD-2004 Targeting CNS and Inflammatory Diseases]]>https://www.newswire.co.kr/newsRead.php?no=616513Fri, 13 Apr 2012 11:12:51 +0900<![CDATA[지엔티파마, 일본 도요타통상과 신약개발 전략적 파트너쉽 체결]]>https://www.newswire.co.kr/newsRead.php?no=616022Thu, 12 Apr 2012 09:26:11 +0900